Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer
Publication
, Conference
Stephens, SJ; Czito, B; Zhang, X; Duffy, E; Malicki, M; Pitcher, B; Niedzwiecki, D; Abbruzzese, J; Uronis, H; Blobe, G; Blazer, DG; Palta, M ...
Published in: International Journal of Radiation Oncology*Biology*Physics
November 2018
Duke Scholars
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2018
Volume
102
Issue
3
Start / End Page
S180 / S180
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Stephens, S. J., Czito, B., Zhang, X., Duffy, E., Malicki, M., Pitcher, B., … Palta, M. (2018). Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer. In International Journal of Radiation Oncology*Biology*Physics (Vol. 102, pp. S180–S180). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2018.07.056
Stephens, S. J., B. Czito, X. Zhang, E. Duffy, M. Malicki, B. Pitcher, D. Niedzwiecki, et al. “Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S180–S180. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.07.056.
Stephens SJ, Czito B, Zhang X, Duffy E, Malicki M, Pitcher B, et al. Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2018. p. S180–S180.
Stephens, S. J., et al. “Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer.” International Journal of Radiation Oncology*Biology*Physics, vol. 102, no. 3, Elsevier BV, 2018, pp. S180–S180. Crossref, doi:10.1016/j.ijrobp.2018.07.056.
Stephens SJ, Czito B, Zhang X, Duffy E, Malicki M, Pitcher B, Niedzwiecki D, Abbruzzese J, Uronis H, Blobe G, Blazer DG, Willett CG, Palta M. Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2018. p. S180–S180.
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2018
Volume
102
Issue
3
Start / End Page
S180 / S180
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences